Roquinimex
Modify Date: 2024-01-09 20:44:14
Roquinimex structure
|
Common Name | Roquinimex | ||
|---|---|---|---|---|
| CAS Number | 84088-42-6 | Molecular Weight | 308.331 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 436.2±45.0 °C at 760 mmHg | |
| Molecular Formula | C18H16N2O3 | Melting Point | 204 °C(dec.) | |
| MSDS | N/A | Flash Point | 217.6±28.7 °C | |
Use of RoquinimexRoquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.IC50 value:Target: TNF alphaProphylactic administration of DSS-treated mice with roquinimex significantly reduced clinical signs of colitis, MDS and the CH-reduction. Moreover, in roquinimex treated animals, the MPO activity was significantly reduced by more than 50% compared to DSS control mice. Notably, therapeutic administration of roquinimex in DSS-treated mice also significantly inhibited the MDS, CH-reduction and MPO activity [2]. Linomide, a synthetic immunomodulator, at concentrations effective in vivo reduces the number of MBP-reactive TNF-alpha and increases MBP-reactive IL-10 and TGF-beta mRNA expressing MNC from MS patients' blood when analysed in vitro. Compared to dexamethasone, Linomide up-regulated levels of blood MNC expressing mRNA of TGF-beta after culture in presence of MBP [3]. |
| Name | 4-hydroxy-N,1-dimethyl-2-oxo-N-phenylquinoline-3-carboxamide |
|---|---|
| Synonym | More Synonyms |
| Description | Roquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.IC50 value:Target: TNF alphaProphylactic administration of DSS-treated mice with roquinimex significantly reduced clinical signs of colitis, MDS and the CH-reduction. Moreover, in roquinimex treated animals, the MPO activity was significantly reduced by more than 50% compared to DSS control mice. Notably, therapeutic administration of roquinimex in DSS-treated mice also significantly inhibited the MDS, CH-reduction and MPO activity [2]. Linomide, a synthetic immunomodulator, at concentrations effective in vivo reduces the number of MBP-reactive TNF-alpha and increases MBP-reactive IL-10 and TGF-beta mRNA expressing MNC from MS patients' blood when analysed in vitro. Compared to dexamethasone, Linomide up-regulated levels of blood MNC expressing mRNA of TGF-beta after culture in presence of MBP [3]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 436.2±45.0 °C at 760 mmHg |
| Melting Point | 204 °C(dec.) |
| Molecular Formula | C18H16N2O3 |
| Molecular Weight | 308.331 |
| Flash Point | 217.6±28.7 °C |
| Exact Mass | 308.116089 |
| PSA | 62.54000 |
| LogP | 1.65 |
| Vapour Pressure | 0.0±1.1 mmHg at 25°C |
| Index of Refraction | 1.686 |
| Hazard Codes | Xn: Harmful; |
|---|---|
| Risk Phrases | R22 |
| Safety Phrases | S36/37 |
| RIDADR | UN 2811 |
| HS Code | 2933790090 |
| HS Code | 2933790090 |
|---|---|
| Summary | 2933790090. other lactams. VAT:17.0%. Tax rebate rate:9.0%. . MFN tariff:9.0%. General tariff:20.0% |
| Roquinimex |
| LS-2616 |
| 1,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide |
| 4-Hydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydro-3-quinolinecarboxamide |
| FCF-89 |
| Linomide |
| 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide |
| N-phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide |
| 3-Quinolinecarboxamide, 1,2-dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl- |
| N-phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide |